BOMXF yields 4.99% · JNJ yields 2.13%● Live data
📍 BOMXF pulled ahead of the other in Year 1
Combined, BOMXF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BOMXF + JNJ for your $10,000?
Bolsa Mexicana de Valores, S.A.B. de C.V. operates cash, listed derivatives, and OTC markets for various asset classes, including equities, fixed income, and exchange traded funds. The company also provides custody, clearing and settlement facilities, and data products for the local and international financial community. It operates the Mexican Stock Exchange that provides facilities and mechanisms as an aid in the relationship of the securities supply and demand, credit certificates, and other documents registered at the National Securities Registry, as well as services for underwriting, offering, and the exchange of the aforementioned securities; and publishes, provides, and maintains information of the securities listed at the Mexican Exchange and at the International Quotations System to the general public. The company's exchange also issues regulation that sets standards, and operative and conduct guidelines to promote fair and equitable market practices at the securities market; and guards its observation and impose disciplinary and corrective measures in case of lack of fulfillment for brokerage firms and the issuers with listed securities at the Mexican Exchange. In addition, it offers central securities depository, custody and settlement of securities, clearing house, price valuation, and risk management services. The company is based in Mexico City, Mexico.
Full BOMXF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.